Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more
Biophytis S.A. (BPTSY) - Net Assets
Latest net assets as of June 2024: $-6.42 Million USD
Based on the latest financial reports, Biophytis S.A. (BPTSY) has net assets worth $-6.42 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.71 Million) and total liabilities ($15.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.42 Million |
| % of Total Assets | -73.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 221.91 |
Biophytis S.A. - Net Assets Trend (2012–2023)
This chart illustrates how Biophytis S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biophytis S.A. (2012–2023)
The table below shows the annual net assets of Biophytis S.A. from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-3.89 Million | -103.51% |
| 2022-12-31 | $-1.91 Million | -133.50% |
| 2021-12-31 | $5.71 Million | -16.50% |
| 2020-12-31 | $6.83 Million | +190.78% |
| 2019-12-31 | $-7.53 Million | -207.42% |
| 2018-12-31 | $7.01 Million | -66.93% |
| 2017-12-31 | $21.19 Million | +368.82% |
| 2016-12-31 | $4.52 Million | -61.26% |
| 2015-12-31 | $11.67 Million | +1133.40% |
| 2014-12-31 | $-1.13 Million | -175.79% |
| 2013-12-31 | $-409.32K | -425.91% |
| 2012-12-31 | $125.60K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biophytis S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1938300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.08 Million | % |
| Other Comprehensive Income | $-25.00K | % |
| Other Components | $13.47 Million | % |
| Total Equity | $-3.86 Million | 100.00% |
Biophytis S.A. Competitors by Market Cap
The table below lists competitors of Biophytis S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mahaka Radio Integra Tbk PT
JK:MARI
|
$4.19 Million |
|
Hifab Group AB Series B
ST:HIFA-B
|
$4.19 Million |
|
Openn Negotiation Ltd
AU:OPN
|
$4.20 Million |
|
Trius Investments Inc
V:TRU
|
$4.20 Million |
|
Pamapol S.A.
WAR:PMP
|
$4.19 Million |
|
RenoWorks Software Inc
PINK:ROWKF
|
$4.19 Million |
|
Make To Win Holding PCL
BK:MTW
|
$4.19 Million |
|
Tadmax Resources Berhad
KLSE:4022
|
$4.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biophytis S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -1,879,000 to -3,857,000, a change of -1,978,000.
- Net loss of 17,026,000 reduced equity.
- New share issuances of 5,541,000 increased equity.
- Other factors increased equity by 9,507,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.03 Million | -441.43% |
| Share Issuances | $5.54 Million | +143.66% |
| Other Changes | $9.51 Million | +246.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biophytis S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-255.17 | $2.08 | x |
| 2014-12-31 | $-737.48 | $2.08 | x |
| 2015-12-31 | $9619.26 | $2.08 | x |
| 2016-12-31 | $2934.84 | $2.08 | x |
| 2017-12-31 | $9236.83 | $2.08 | x |
| 2018-12-31 | $2105.00 | $2.08 | x |
| 2019-12-31 | $-1776.07 | $2.08 | x |
| 2020-12-31 | $457.75 | $2.08 | x |
| 2021-12-31 | $194.01 | $2.08 | x |
| 2022-12-31 | $-42.99 | $2.08 | x |
| 2023-12-31 | $-28.41 | $2.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biophytis S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-126.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-483.53K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-599.05K |
| 2015 | -44.73% | 0.00% | 0.00x | 1.16x | $-6.40 Million |
| 2016 | -174.85% | 0.00% | 0.00x | 1.85x | $-8.41 Million |
| 2017 | -53.77% | 0.00% | 0.00x | 1.22x | $-13.53 Million |
| 2018 | -198.76% | 0.00% | 0.00x | 3.11x | $-14.69 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.20 Million |
| 2020 | -371.81% | 0.00% | 0.00x | 3.96x | $-26.20 Million |
| 2021 | -543.19% | 0.00% | 0.00x | 6.32x | $-31.74 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.03 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.64 Million |
Industry Comparison
This section compares Biophytis S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biophytis S.A. (BPTSY) | $-6.42 Million | 0.00% | N/A | $4.19 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |